Generic Industry Calls on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming

Published Online: Thursday, September 19, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (Sept. 19, 2013) —The Generic Pharmaceutical Association (GPhA) has filed an official Citizen Petition with the Food and Drug Administration (FDA) detailing its position on biosimilar naming. The petition recommends that all biosimilars approved by the agency share the same international non-proprietary name (INN) as the biologic products to which they refer, because by definition they are “highly similar” to the reference biologics and have no clinically meaningful differences that require a unique name.

“It is simple: biosimilars have no clinically meaningful difference from the reference product, so they should have the same name,” said Ralph G. Neas, president and CEO of the Generic Pharmaceutical Association. “This approach works in Europe, it has worked in the United States for chemical drugs, and it should be the standard worldwide. To upset the naming system in place risks engendering confusion and would have a major negative impact throughout the global pharmaceutical supply chain, potentially jeopardizing patient access across the globe.”

Despite assertions to the contrary, the petition states that unique names will not enhance safety. Biosimilars using the same INN as their reference products have been on the market in Europe since 2006 with a proven safety record, and there have been no issues with traceability or pharmacovigilance. In the United States, pharmaceutical and biologic products are successfully traced using national drug codes (NDCs), batch and lot numbers.

In addition, the Citizen Petition points out that existing INN policy administered by the World Health Organization (WHO) assures practitioners worldwide that the prescribed product has the same active ingredient and clinical effect as the reference product. The GPhA petition holds that the global INN system to keep patients safe, which has been in place for 50 years and used in scores of countries around the world, should not be changed for one subset class of products.

Consistent biosimilar naming aligns with previous FDA recommendations. In 2006, FDA issued a policy paper to the World Health Organization (WHO), supporting the original purpose of the INN, to identify active ingredients, and reject the use of non-proprietary names to communicate interchangeability.

GPhA continues to encourage a dialogue among FDA and other stakeholders to explore the best way to support the existing system for pharmacovigilance and optimize data collection that ensures patient safety.

For more information on biosimilars, visit: http://www.gphaonline.org/issues/biosimilars.

References:
GPhA Citizen Petition
Related Articles
Fred Eckel, RPh, MS, Editor-in-Chief of Pharmacy Times, reflects on how pharmacists will be affected by FDA approvals of biosimilars.
The FDA’s March 6, 2015, Zarxio approval brought biosimilars into the spotlight once again, although Zarxio and other biosimilars continue to face hurdles. Community pharmacists should remain aware of the therapies in order to better assist their patients.
With many blockbuster biologics’ patents expiring, pharmacists must educate themselves so they can properly inform patients about the safe and effective use of biosimilars.
Could proponents of this legislation be more interested in protecting market share in the name of patient safety?
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$